These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37243465)

  • 1. Editorial: proactive anti-TNF drug monitoring in IBD-Ready for prime time?
    Roblin X; Nancey S
    Aliment Pharmacol Ther; 2023 Jun; 57(12):1453-1454. PubMed ID: 37243465
    [No Abstract]   [Full Text] [Related]  

  • 2. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
    Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
    Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: proactive anti-TNF drug monitoring in IBD-Ready for the prime time? Authors' reply.
    Sethi S; Kumar A; Dias S; Blackwell J; Brookes MJ; Segal JP
    Aliment Pharmacol Ther; 2023 Jun; 57(12):1455-1456. PubMed ID: 37243471
    [No Abstract]   [Full Text] [Related]  

  • 4. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advantages of Proactive Therapeutic Drug Monitoring in a Prospective Cohort of Children With Inflammatory Bowel Disease Treated With Anti-Tumour Necrosis Factor.
    Gasparetto M; Burgess N; Naik S; Studart D; Kadir A; Croft N; Sanderson I; Deb P
    J Pediatr Gastroenterol Nutr; 2022 Apr; 74(4):484-489. PubMed ID: 35129158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DDS Perspective: My Take on Therapeutic Drug Monitoring in IBD.
    Abreu MT
    Dig Dis Sci; 2019 Dec; 64(12):3377-3381. PubMed ID: 31628571
    [No Abstract]   [Full Text] [Related]  

  • 7. Is Proactive Therapeutic Drug Monitoring Ready for the Spotlight in Inflammatory Bowel Disease? Follow the Data.
    Battat R; Long MD
    Am J Gastroenterol; 2021 Oct; 116(10):2029-2031. PubMed ID: 34515666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy.
    Yao J; Jiang X; You JHS
    Inflamm Bowel Dis; 2021 Jan; 27(2):275-282. PubMed ID: 32311018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy.
    Papamichael K; Cheifetz AS
    Am J Gastroenterol; 2017 May; 112(5):673-676. PubMed ID: 28220781
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?
    Strik AS; Berends SE; Löwenberg M
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):885-891. PubMed ID: 31305158
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.
    Adar T; Faleck D; Sasidharan S; Cushing K; Borren NZ; Nalagatla N; Ungaro R; Sy W; Owen SC; Patel A; Cohen BL; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2019 Apr; 49(7):873-879. PubMed ID: 30773667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?
    Papamichael K; Osterman MT; Siegel CA; Melmed GY; Dubinsky MC; Colombel JF; Hanauer SB; Cheifetz AS
    Gastroenterology; 2018 Mar; 154(4):1201-1202. PubMed ID: 29432749
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.
    Strik AS; Bots SJ; D'Haens G; Löwenberg M
    Expert Rev Clin Pharmacol; 2016; 9(3):429-39. PubMed ID: 26681400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fighting the Hype for Predictors of Efficacy in Inflammatory Bowel Disease.
    Lopetuso LR; Gasbarrini A
    Inflamm Bowel Dis; 2020 Apr; 26(5):764-765. PubMed ID: 31689346
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial: Gastrointestinal 2020: Novel inflammatory bowel disease treatments and therapeutic drug monitoring.
    Torres J; Declerck P
    Curr Opin Pharmacol; 2020 Dec; 55():iii-vi. PubMed ID: 33357460
    [No Abstract]   [Full Text] [Related]  

  • 17. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
    Kanis SL; Modderman S; Escher JC; Erler N; Beukers R; de Boer N; Bodelier A; Depla ACTM; Dijkstra G; van Dijk ARM; Gilissen L; Hoentjen F; Jansen JM; Kuyvenhoven J; Mahmmod N; Mallant-Hent RC; van der Meulen-de Jong AE; Noruzi A; Oldenburg B; Oostenbrug LE; Ter Borg PCJ; Pierik M; Romberg-Camps M; Thijs W; West R; de Lima A; van der Woude CJ;
    Gut; 2021 Jul; 70(7):1266-1274. PubMed ID: 33046558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
    Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P
    Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Carman N; Mack DR; Benchimol EI
    Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations in Insurance Policies Regarding Adherence to the AGA Guideline for Therapeutic Drug Monitoring in IBD.
    Yadav A; Vasquez P; Dolgin NH; Falchuk KR; Feuerstein JD
    J Clin Gastroenterol; 2019 Jul; 53(6):e239-e242. PubMed ID: 30439759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.